Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Complete and robust ovulation inhibition with NuvaRing.

S Killick1

  • 1Department of Obstetrics and Gynaecology, The Princess Royal Hospital, Hull, UK.

The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception
|March 28, 2003
PubMed
Summary

NuvaRing, a vaginal contraceptive ring, effectively prevents ovulation. Pharmacokinetic studies show lower ethinylestradiol exposure compared to combined oral contraceptives, while maintaining comparable progestogen exposure for robust contraception.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discussion.

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception·2017
Same author

Cryptic splicing events in the iron transporter ABCB7 and other key target genes in SF3B1-mutant myelodysplastic syndromes.

Leukemia·2016
Same author

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies.

Blood cancer journal·2015
Same author

Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression.

Leukemia·2015
Same author

Whole-exome sequencing in del(5q) myelodysplastic syndromes in transformation to acute myeloid leukemia.

Leukemia·2013
Same author

Effects of L-leucine in 5q- syndrome and other RPS14-deficient erythroblasts.

Leukemia·2012

Area of Science:

  • Reproductive Endocrinology
  • Pharmacokinetics and Pharmacodynamics
  • Contraception

Background:

  • NuvaRing is a novel contraceptive vaginal ring releasing ethinylestradiol (EE) and etonogestrel (ENG).
  • Comparison with combined oral contraceptives (COCs) is essential for understanding its efficacy and safety profile.

Purpose of the Study:

  • To compare the pharmacokinetics of NuvaRing with a specific combined oral contraceptive.
  • To evaluate the pharmacodynamic effects of NuvaRing on ovarian function under various usage scenarios.

Main Methods:

  • A randomized pharmacokinetic study comparing NuvaRing to a COC (30 mcg EE/150 mcg desogestrel).
  • Pharmacodynamic studies assessing ovulation inhibition during recommended (3-week) and altered (extended use, early removal, delayed insertion) NuvaRing use.

Related Experiment Videos

Main Results:

  • NuvaRing showed lower maximum EE (30%) and ENG (40%) levels compared to the COC.
  • Systemic progestogen exposure was comparable due to higher ENG bioavailability via vaginal administration.
  • EE bioavailability was similar, resulting in half the EE exposure with NuvaRing compared to the COC.
  • NuvaRing consistently inhibited ovulation during recommended 3-week use and an additional 2 weeks.
  • Altered use patterns, including 3-day use or delayed insertion, also effectively inhibited ovulation.

Conclusions:

  • NuvaRing is a robust contraceptive method that effectively inhibits ovulation.
  • Its pharmacokinetic profile offers reduced ethinylestradiol exposure compared to some COCs.
  • Flexible usage patterns demonstrate consistent ovulation suppression, enhancing its contraceptive reliability.